Skip to content

Study · Non-randomized trial · n = 13 · 2011

6 results

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK

The Journal of clinical endocrinology and metabolism13 Oct 2010Cited by 42 (Europe PMC)

PMID20943777 (opens in a new tab)PMCIDPMC3038486 (opens in a new tab)DOI10.1210/jc.2010-1587 (opens in a new tab)PepBankPUB-20943777
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, 2 weeks of tesamorelin 2 mg daily increased mean overnight growth hormone (GH).

    In plain wordsIn healthy men, tesamorelin raised overnight growth hormone levels.

    Peptide
    Tesamorelin
    Outcome
    IncreaseMean overnight GH change
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 mg once daily · subcutaneous · 2 wkAs given in this study (human).

    Measurements

    Mean overnight GH change
    0.5 μg/liter
    tesamorelin

    Source sentences

    Summary
    Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log(10) GH peak area (change +0.4 ± 0.1 log(10) μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008).
    1 context sentence
    Summary · context
    Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy men, tesamorelin increased the average log10 GH peak area.

    In plain wordsIn healthy men, tesamorelin increased the size of growth hormone pulses.

    Peptide
    Tesamorelin
    Outcome
    IncreaseAverage log10 GH peak area change
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 mg once daily · subcutaneous · 2 wkAs given in this study (human).

    Measurements

    Average log10 GH peak area change
    0.4 log(10) μg/liter
    tesamorelin

    Source sentences

    Summary
    Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log(10) GH peak area (change +0.4 ± 0.1 log(10) μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008).
    1 context sentence
    Summary · context
    Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy men, tesamorelin increased basal GH secretion.

    In plain wordsIn healthy men, tesamorelin raised the steady background release of growth hormone.

    Peptide
    Tesamorelin
    Outcome
    IncreaseBasal GH secretion change
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 mg once daily · subcutaneous · 2 wkAs given in this study (human).

    Measurements

    Basal GH secretion change
    0.008 μg/liter · min
    tesamorelin

    Source sentences

    Summary
    Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log(10) GH peak area (change +0.4 ± 0.1 log(10) μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008).
    1 context sentence
    Summary · context
    Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy men, tesamorelin increased IGF-I.

    In plain wordsIn healthy men, tesamorelin raised IGF-I levels.

    Peptide
    Tesamorelin
    Outcome
    IncreaseIGF-I change
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 mg once daily · subcutaneous · 2 wkAs given in this study (human).

    Measurements

    IGF-I change
    181 μg/liter
    tesamorelin

    Source sentences

    Summary
    IGF-I increased by 181 ± 22 μg/liter (P < 0.0001).
    1 context sentence
    Summary · context
    Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy men, tesamorelin did not significantly change insulin-stimulated glucose uptake in a euglycemic clamp.

    In plain wordsIn healthy men, tesamorelin did not significantly change how well the body took up glucose with insulin.

    Peptide
    Tesamorelin
    Outcome
    No significant changeInsulin-stimulated glucose uptake
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once daily · subcutaneous · 2 wkAs given in this study (human).

    Source sentences

    Summary
    nor insulin-stimulated glucose uptake (P = 0.61) was significantly affected by tesamorelin.
    1 context sentence
    Summary · context
    Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy men, tesamorelin did not significantly change fasting glucose.

    In plain wordsIn healthy men, tesamorelin did not significantly change fasting glucose.

    Peptide
    Tesamorelin
    Outcome
    No significant changeFasting glucose
    Study

    n = 13

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once daily · subcutaneous · 2 wkAs given in this study (human).

    Source sentences

    Summary
    Neither fasting glucose (P = 0.93)
    1 context sentence
    Summary · context
    Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT00850564

Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Massachusetts General Hospitaln = 15Feb 2009 to Apr 2010

Healthy Volunteers

Trial pageClinicalTrials.govUpdated 19 Apr 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.